Transcatheter Arterialization of the Deep Veins for Chronic Limb-Threatening Ischemia: A Case Series of the Direct Cost Associated With Limb Salvage
- PMID: 40904764
- PMCID: PMC12404106
- DOI: 10.14740/jmc5155
Transcatheter Arterialization of the Deep Veins for Chronic Limb-Threatening Ischemia: A Case Series of the Direct Cost Associated With Limb Salvage
Abstract
Our study aims to estimate the long-term cost of procedurally successful transcatheter arterialization of the deep veins (TADV) coupled with adjunct therapy. Patients with no conventional endovascular/open options were considered for TADV. TADV index procedure cost, cost of subsequent procedures and wound care/adjuncts were collected. Cost data were obtained from Medicare claims and other published sources. All patients in the study had limb salvage 180 days after TADV. Success was defined as lime salvage with no more than a transmetatarsal amputation of the affected limb. The average cost of the procedure was $320,850. The average hospital cost (hospitalization and wound care adjuncts) was $895,546. The overall average total cost was $1,216,396. TADV and associated multidisciplinary wound care approach for "no option" chronic limb-threatening ischemia does not appear to be a cost-effective strategy, with an average total cost of over 1 million dollars per patient.
Keywords: Amputation; Cost; Deep venous arterialization; Limb salvage; Medicare; Transcatheter arterialization of the deep veins.
Copyright 2025 Authors.
Conflict of interest statement
None to declare.
Similar articles
-
Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia.N Engl J Med. 2023 Mar 30;388(13):1171-1180. doi: 10.1056/NEJMoa2212754. N Engl J Med. 2023. PMID: 36988592
-
Outcomes following deep venous arterialization in Medicare patients with chronic limb-threatening ischemia.J Vasc Surg. 2025 Sep;82(3):1007-1013. doi: 10.1016/j.jvs.2025.04.003. Epub 2025 Apr 11. J Vasc Surg. 2025. PMID: 40220975
-
1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies.JACC Cardiovasc Interv. 2025 Jul 14;18(13):1675-1685. doi: 10.1016/j.jcin.2025.05.004. JACC Cardiovasc Interv. 2025. PMID: 40669969
-
Editor's Choice - Short and Midterm Outcomes of Percutaneous Deep Venous Arterialisation for No Option Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-Analysis.Eur J Vasc Endovasc Surg. 2025 Feb;69(2):284-292. doi: 10.1016/j.ejvs.2024.08.001. Epub 2024 Aug 8. Eur J Vasc Endovasc Surg. 2025. PMID: 39121906
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials